Market Opportunity Target the tick-borne disease diagnostics market, leveraging Inanovate's Bio-ID800/LAS platform to offer a comprehensive diagnostic and treatment monitoring solution for Lyme disease and related infections, addressing a clear early-diagnosis pain point.

Capital & Growth Capitalize on the recent Series C funding and a modest revenue base to propose scalable partnerships, pilot programs, and co-development opportunities with larger diagnostics players seeking a proteomics-based diagnostics edge.

Geographic Focus Prioritize business development efforts in the United States with emphasis on the Midwest and Southeast regions where healthcare systems are receptive to rapid diagnostic deployment, while exploring contract manufacturing and distributed testing arrangements in Chapel Hill and Sioux Falls.

Clinical & Data Position Bio-ID800/LAS as a one-stop solution for diagnosis and treatment monitoring, offering validation partnerships, clinical studies, and data collaboration opportunities to strengthen regulatory submissions and market adoption.

Strategic Partnerships Leverage the small, agile team size to pursue strategic alliances with larger biotech and medical device firms for joint development, white-labeling, or licensing of the proteomics platform, expanding sales channels without substantial headcount increases.